ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023
Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: The cardiovascular health study.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 42 citations in OpenAlex.
- Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease.Journal of neuroinflammation · 2025Trial
- Associations of serum neurofilament light chain concentration with able life and healthy life in older adults: The Cardiovascular Health Study.Archives of gerontology and geriatrics · 2026Article
- The interplay of air pollution with plasma neurodegenerative markers and metabolome for dementia, Parkinson's disease and all-cause mortality risks and transitions: The UK Biobank study.Ecotoxicology and environmental safety · 2026Article
- Purpose in life and blood-based biomarkers of brain health.The journals of gerontology. Series B, Psychological sciences and social sciences · 2026Article
- Development of a mortality prediction nomogram for dementia patients using the MIMIC-IV database.Scientific reports · 2026Article
- Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Circulating Biomarkers of Neurodegeneration and All-Cause and Dementia-Specific Mortality.Neurology · 2026Article
- Dementia risk prediction in individuals with prediabetes or diabetes: A novel multi-protein score with biological pathway analysis.General psychiatry · 2026Article
- Circulating neurodegenerative brain injury markers and hip fracture and fall hospitalizations: the Cardiovascular Health Study.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Article
- Subclinical cardiac dysfunction and circulating markers of brain injury in older adults: The cardiovascular health study.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2025Article
- Blood biomarkers of Alzheimer's disease and progression across different stages of cognitive decline in the community.Nature communications · 2025Article
- Prognostic value of plasma glial fibrillary acidic protein in cognitively unimpaired older adults: Results from the A4 study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Preclinical development of an immunoassay for the detection of TREM2: a new biomarker for Alzheimer's disease.Scientific reports · 2025Article
- Review
- Olfaction and Plasma Biomarkers of Alzheimer Disease and Neurodegeneration in the Atherosclerosis Risk in Communities Study.Neurology · 2025Article
- Blood-based biomarkers of Alzheimer's disease and incident dementia in the community.Nature medicine · 2025Article
- Multimorbidity patterns and blood biomarkers of Alzheimer's disease in community-dwelling cognitively unimpaired older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Deep learning-based segmentation in MRI-(immuno)histological examination of myelin and axonal damage in normal-appearing white matter and white matter hyperintensities.Brain pathology (Zurich, Switzerland) · 2025Article
- Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort.Brain communications · 2025Article
- Meaning in life and neurobiomarkers of brain health in the UK Biobank.Journal of Alzheimer's disease : JAD · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 2 countries.
Funding
Abstract
introductionCirculating neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) have been independently associated with dementia risk. Their additive association, and their associations with dementia-specific mortality, have not been investigated.
methodsWe associated serum NfL, GFAP, total tau ,and ubiquitin carboxyl-terminal hydrolase-L1, measured in 1712 dementia-free adults, with 19-year incident dementia and dementia-specific mortality risk, and with 3-year cognitive decline.
resultsIn adjusted models, being in the highest versus lowest tertile of NfL or GFAP associated with a hazard ratio (HR) of 1.49 (1.20-1.84) and 1.38 (1.15-1.66) for incident dementia, and 2.87 (1.79-4.61) and 2.76 (1.73-4.40) for dementia-specific mortality. Joint third versus first tertile exposure further increased risk; HR = 2.06 (1.60-2.67) and 9.22 (4.48-18.9). NfL was independently associated with accelerated cognitive decline. DISCUSSION: Circulating NfL and GFAP may, independently and jointly, provide useful clinical insight regarding dementia risk and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.